I-131 tositumomab

Expert Opinion on Biological Therapy

Volumn 10, Issue 8, 2010, Pages 1271-1278

  William, Basem M ^a   Bierman, Philip J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Follicular lymphoma; I 131 tositumomab; Lymphoma; Monoclonal antibody; Radioimmunoconjugates; Radioimmunotherapy; Transplant

Indexed keywords

CARMUSTINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; MELPHALAN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; ANTINEOPLASTIC AGENT; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ANEMIA; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CELL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVIEW; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTOPENIA; ANIMAL; LYMPHOMA, FOLLICULAR; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, FOLLICULAR; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 77954687202     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.504707     Document Type: Review

References (66)

1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717-720
2. Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 2003;4:161-168
3. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918-3927
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545
5. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684
6. Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008;45:118-125
7. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918
8. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non-Hodgkin's lymphoma. Cancer 1997;80:2311-2320
9. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423
10. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732
11. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25(15):1986-1992
12. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824-4831
13. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833
14. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932
15. Ersboll J, Schultz HB, Pedersen-Bjergaard J, Nissen NI. Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression. Eur J Haematol 1989;42:155-163
16. Vose JM. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 2004;9:160-172
17. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43:1507-1529
18. Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999;11:375-380
19. Zalutsky MR, Garg PK, Narula AS. Labeling monoclonal antibodies with halogen nuclides. Acta Radiol Suppl 1990;374:141-145
20. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab. BioDrugs 2003;17:290-295
21. Colcher D. Centralized radiolabeling of antibodies for radioimmunotherapy. J Nucl Med 1998;39(8 Suppl):11S-3S
22. Press OW, Farr AG, Borroz KI, et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906-4912
23. Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994;83:1390-1397
24. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123-2129
25. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51:15-24
26. Ivanov A, Krysov S, Cragg MS, Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res 2008;14(15):4925-4934
27. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998;39(8 Suppl):14S-20S
28. Wahl RL. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. J Nucl Med 1998;39(8 Suppl):1S
29. Dewaraja YK, Wilderman SJ, Koral KF, et al. Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study. Cancer Biother Radiopharm 2009;24:417-426
30. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-1981
31. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-1266
32. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003;101:391-398
33. Vose JM, Wahl RL, Saleh M, et al. Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316-1323
34. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712-719
35. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3928
36. Kaminski MS, Kauf TL, Zelenetz AD, Vose JM. Treatment of transformed and refractory low-grade lymphoma with BexxarTM therapy is associated with improvements in quality of life. Blood 2001;98:683a
37. Kaminski MS, Tuck M, Estes J, et al. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: Median 10 year follow-up results. ASH Annual Meeting Abstracts 20 November 2009, 2009;114:3759
38. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-449
39. Kaminski MS, Zelenetz AD, Leonard J, et al. Bexxar radioimmunotherapy produces a substantial number of durable complete responses in patients with multiply relapsed or refractory low grade or transformed low grade non-Hodgkin's lymphoma. Blood 2002;100:356a
40. Link B, Kaminski MS, Coleman M, Leonard JP. Phase II study of CVP followed by tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol 2004;22(14 Suppl):562a
41. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696-5704
42. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-4149
43. Press OW, Eary JF, Gooley T, et al. A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934-2942
44. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005;23:461-467
45. Vose J, Bierman P, Bociek G, et al. Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):8013
46. Juweid ME, Stadtmauer E, Hajjar G, et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 1999;5(10 Suppl):3292S-303S
47. Rao DV, Howell RW. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides. J Nucl Med 1993;34:1801-1810
48. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol 2003;30(2 Suppl 4):10-21
49. Gregory SA, Hohloch K, Gisselbrecht C, et al. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. Oncologist 2009;14(Suppl 2):4-16
50. Cheson BD. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs 2005;19:309-322
51. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164
52. Iagaru A, Mittra ES, Ganjoo K, et al. 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol 2010;12:198-203
53. Leonard JP, Frenette G, Dillman RO, Gregory SA. Interim safety and efficacy results of BexxarTM in a large multicenter expanded access study. Blood 2001;98:133a
54. Leonard JP, Zelenetz AD, Vose JM, et al. (tositumomab and iodine I 131 tositumomab) results in durable long-term responses in patients with poor prognosis, multiple relapsed (Rel) and refractory (Ref) low-grade or transformed low-grade non-Hodgkins Lymphoma (NHL). Blood 2001;98:683a
55. Kaminski MS, Gribbin T, Ross CW, et al. I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions. Proc Am Soc Clin Oncol 1998;17:2a
56. Kaminski MS. Tolerance of treatment subsequent to frontline BexxarTM (tositumomab and iodine I-131 tositumomab) in patients (pts) with follicular lymphoma. Blood 2001;98:603a
57. Schenkein DP, Leonard J, Harwood S. Interim safety results of BexxarTM in a large multicenter expanded access study. Proc Am Soc Clin Oncol 2001;20:285a 62
58. Gregory SA, Coleman M, Dillman RO. BexxarTM is a well-tolerated therapy in elderly patients with low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 2001;98:605a 63
59. Kaminski MS, Zelenetz AD, Press OW. Multicenter, Phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 64 1998;92(Suppl 1):316a
60. Kaminski MS, Gregory SA, Fehrenbacher L. Acute and delayed hematologic toxicities associated with BexxarTM therapy are modest: overall 65 experience in patients with low-grade and transformed low-grade NHL. Blood 2001;98:339a
61. Gregory SA, Leonard J, Coleman M, et al. Relationship of degree of bone marrow involvement with hematologic toxicity in patients with non-Hodgkin's lymphoma treated with tositumomab and iodine I 131 tositumomab therapy. Proc Am Soc Clin Oncol 2003;22:2314a
62. Gregory SA, Zelenetz AD, Knox SJ, et al. BexxarTM is an effective and well tolerated therapy in elderly patients with non-Hodgkin lymphoma (NHL). Am Soc Clin Oncol 2001;20:285a
63. Kaminski MS, Bennett J, Tuck M, et al. Lack of treatment-related MDS/AML in patients with follicular lymphoma after frontline therapy with tositumomab and iodine I 131 tositumomab. Proc Am Soc Clin Oncol 2003;22:a2313
64. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906
65. Rutar FJ, Augustine SC, Kaminski MS, et al. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma 2001;2:164-172
66. Morschhauser F, Dreyling M, Rohatiner A, et al. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist 2009;14(Suppl 2):17-29